ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1223

Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Abstract Number: 2065

Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
Abstract Number: 1238

Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Abstract Number: 0814

Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Abstract Number: 0199

Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abstract Number: 0783

Pain reduction and functional improvements following a non-invasive biomechanical intervention for gait rehabilitation may explain a reduction in healthcare claims. An observational study
Abstract Number: 2261

Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Abstract Number: 1870

Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis
Abstract Number: 1803

Patching of Damaged Meniscus and Cartilage of Osteoarthritic Animals by MM-II, a Dispersion of Empty Large Multilamellar Liposomes
Abstract Number: 1724

Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Abstract Number: 0925

Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Abstract Number: 1259

Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Abstract Number: 1248

Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease
Abstract Number: 0561

Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Abstract Number: 1445

Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].